Investigation of the assortment of medicines for the treatment of chronic obstructive pulmonary disease in the pharmaceutical market of Ukraine
Keywords:chronic obstructive pulmonary disease, bronchodilator agents, research of the pharmaceutical market, marketing
The aim of the work – to analyze the assortment of medicines for the treatment of chronic obstructive pulmonary disease (COPD) (bronchodilator therapy (BT). in the modern pharmaceutical market of Ukraine.
Materials and Methods. The study of the assortment of drugs was carried out according to the State Register of Medicines of Ukraine, the directory of medicines Compendium online, Anatomical Therapeutic Chemical classification (group of medicines code R03 – remedies for the treatment of obstructive respiratory diseases), online resources for the search of drugs in pharmacies of Ukraine “GeoApteka” and “Tabletki.ua”. The following methods are used: marketing, mathematical and statistical, logical generalization and graphic.
Results. Comprehensive marketing evaluation of the domestic pharmaceutical market for medicines used for the treatment of COPD (BT).Conclusions. According to the State Register of Medicines of Ukraine, as of the end of 2019, there are 36 TN medicines for the treatment of COPD (BT) in Ukraine. Analysis of the assortment of drugs showed that foreign pharmaceutical production was dominated by pharmaceutical products in Ukraine (64 %). Among the importing countries of drugs, Germany (31 %), Spain (18 %) and India (13 %) take the first place in the nomenclature of medicines. The leader among domestic manufacturing companies is Multispray LLC, Kharkiv (31 %). The share of mono-preparation for COPD (BT) treatment in the domestic pharmaceutical market is 80 %, two-component drugs – 14 % and combination drugs – 6 %. Since the pharmaceutical market of Ukraine was dominated by overseas medicines used in COPD bronchodilation therapy, the results of the analysis of the assortment confirm the relevance of the development of a new domestic drug that can be used in the treatment of patients with this disease.
Tolokh, O. S. (2017). Khronichne obstruktyvne zakhvoriuvannia lehen: novi rishennia starykh problem [Chronic obstructive pulmonary disease: new solutions to old problems]. Klinichna imunolohiia. Alerholohiia. Infektolohiia, (1), 16-22. [in Ukrainian].
Vsesvitnii den borotby proty KhOZL – 17 lystopada [World COPD Day is November 17th]. [in Ukrainian]. http://www.medcv.gov.ua/archives/18875
Sniehirov, P. (2019). KhOZL kriz pryzmu GOLD-2019: aktualni problemy diahnostyky ta likuvannia [COPD through the GOLD-2019 prism: topical problems in diagnosis and treatment]. Ukrainskyi medychnyi chasopys, (2), 26-29.
Khronichne obstruktyvne zakhvoriuvannia lehen. [Chronic obstructive pulmonary disease]. Farmatsevtychna entsyklopediia. https://www.pharmencyclopedia.com.ua/article/8335/xronichna-obstruktivna-xvoroba-legen-xobl. [in Ukrainian].
Tkachenko, V. I., Kuharchuk, K. N. (2015). Khronichne obstruktyvne zakhvoriuvannia lehen – pidkhody do farmakoterapii zahostrennia [Chronic obstructive pulmonary disease - approaches to pharmacotherapy of exacerbation]. Semeinaya meditsina, (1), 126-129. [in Ukrainian].
Derzhavnyi reiestr likarskykh zasobiv Ukrainy [State register of medicines of Ukraine]. [in Ukrainian]. http://www.drlz.kiev.ua
(2018). Kompendium. Lekarstvennye preparaty. [Compendium. Medicines]. [in Russian]. http://compendium.com.ua
Yakovleva, L. V., Bondarenko, D. V. (2015). Analiz assortimenta preparatov dlya lecheniya KhOBL na farmatsevticheskom rynke i v gosudarstvennom formulyare Ukrainy [Analysis of the range of drugs for copd treatment in the pharmaceutical market and the national formulary of Ukraine]. Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, (2), 76-82. [in Russian].
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)